Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION Breast02
NCT05374512Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- May 2022
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of datopotamab deruxtecan in triple negative breast cancer (TNBC), sponsored by AstraZeneca. Started May 2022; status: active, not recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05374512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05374512.